Harnessing Oncolytic Viruses for Targeted Therapy in Triple-Negative Breast Cancer

Area of Science:

• Oncology
• Virology
• Immunotherapy

Background:

• Triple-negative breast cancer (TNBC) is an aggressive malignancy with limited treatment options.
• Traditional therapies like chemotherapy face challenges with resistance and efficacy in TNBC.
• Oncolytic viruses (OVs) are emerging as a promising biological therapy for various cancers.

Purpose of the Study:

• To review recent progress in the application of oncolytic viruses (OVs) for precision treatment of triple-negative breast cancer (TNBC).
• To highlight the potential of OVs as an alternative therapeutic strategy for TNBC.

Main Methods:

• Literature review of recent studies on oncolytic viruses in breast cancer treatment.
• Focus on studies specifically investigating OV efficacy and mechanisms in TNBC models.
• Analysis of OV-mediated anti-tumor effects, including direct tumor cell lysis and immune stimulation.

Main Results:

• OVs demonstrate selective tumor cell killing and immune response stimulation, showing anti-tumor effects.
• OV efficacy in selected cancers has been comparable to surgery, radiotherapy, or chemotherapy.
• Growing evidence suggests OVs are effective in preclinical and clinical settings for breast cancer.

Conclusions:

• Oncolytic viruses represent a viable and innovative therapeutic approach for triple-negative breast cancer.
• Further research and clinical trials are warranted to fully establish OVs as a standard treatment for TNBC.
• OVs offer a promising avenue for precision medicine in managing aggressive breast cancer subtypes.